ADMA Biologics, Inc. ADMA

Last month I sold my shares at 3.60 at the open and bought them back at 2.75 thinking it was a great deal. I never expected this stock to drop to 1.99. I fully expect ADMA to relive some of its old glory with some positive news. Holding long and strong.

https://www.tickerreport.com/banking-finance/6464176/principal-financial-group-inc-invests-246000-in-adma-biologics-inc-nasdaqadma.html

ADMA collected plasma and conducted R&D to help the Plasma Alliance develop this therapy.
https://www.biopharmadive.com/news/takeda-nih-hyperimmune-plasma-coronavirus-trial/586761/

https://www.fiercebiotech.com/biotech/can-a-plasma-based-treatment-boost-remdesivir-nih-starts-phase-3-trial-to-find-out

ADMA is working with the Plasma Alliance on this COVID-19 Hyperimmune medicine. They are part of an alliance of 11 plasma companies.
https://www.prnewswire.com/news-releases/first-patient-enrolled-in-nih-phase-3-trial-to-evaluate-potential-covid-19-hyperimmune-medicine-301148902.html

ADMA CEO, Founder and President Adam Grossman in a Plasma Alliance video.
https://www.covig-19plasmaalliance.org/videos/ALLIANCE_v5.mp4

https://pennystocks.com/featured/2020/10/07/top-penny-stocks-to-watch-biotech-stocks-surge-higher-october-7-2020/

Biotech Penny Stocks To Watch #2: ADMA Biologics Inc.

Shares of ADMA Biologics Inc. (NASDAQ: ADMA) is another one of the biotech penny stocks that have been on the radar for a few weeks now. It was also one of the top penny stocks on Robinhood to watch at the start of the week. If you recall, there was a big boom in plasma stocks for a brief period this summer. A number of these stocks took off in light of comments made by the U.S. President at the time. Last month ADMA launched a COVID-19 ImmunoRank Neutralization MICRO-ELISA. It’s a fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma.

With a recent surge of attention on coronavirus penny stocks, ADMA is back in the mix. Trading volumes have picked up over the last few weeks and shares have climbed nearly 30%. One of the points of resistance for the stock has been its 50 day moving average. As you can see in the stock chart for the last 6 months, the 50-Day (in yellow) has been a point where ADMA stock has tested and failed at, with a few exceptions. Obviously, it wasn’t able to hold those levels and came back down soon after.

What’s brought a bigger focus on the company as of late has been some analyst actions. Earlier this month, analysts at Raymond James maintained their rating of Outperform on the penny stock. However, the firm did lower its price target to $7 from $9. Given these recent developments, the sympathy momentum from coronavirus, and key technical levels, can ADMA stock continue higher in October?

“Investors should also keep an eye on sector updates as ADMA has historically followed its peers on positive news.”
https://oracledispatch.com/2020/10/06/adma-biologics-inc-nasdaqadma-finding-strong-support/

When the trial finally starts it could be a catalyst. ADMA assisted the Takeda led plasma alliance with plasma collection and research and development. This article is sleazy 3 weeks old so news should be forthcoming.
https://kfgo.com/2020/09/17/takeda-led-covid-19-plasma-product-to-begin-trial-this-month/

ADMA was oversold so this is a correction. It will fall back into the high 2’s low 3’s trading range in the absence of news.